Types of MS (Photo credit: Wikipedia)
Scientists at The New York Stem Cell Foundation (NYSCF) Research Institute are one step closer to creating a viable cell replacement therapy for multiple sclerosis from a patient’s own cells.
For the first time, NYSCF scientists generated induced pluripotent stem (iPS) cells lines from skin samples of patients with primary progressive multiple sclerosis and further, they developed an accelerated protocol to induce these stem cells into becoming oligodendrocytes, the myelin-forming cells of the central nervous system implicated in multiple sclerosis and many other diseases.
Existing protocols for producing oligodendrocytes had taken almost half a year to produce, limiting the ability of researchers to conduct their research. This study has cut that time approximately in half, making the ability to utilize these cells in research much more feasible.
Stem cell lines and oligodendrocytes allow researchers to “turn back the clock” and observe how multiple sclerosis develops and progresses, potentially revealing the onset of the disease at a cellular level long before any symptoms are displayed. The improved protocol for deriving oligodendrocyte cells will also provide a platform for disease modeling, drug screening, and for replacing the damaged cells in the brain with healthy cells generated using this method.
“We are so close to finding new treatments and even cures for MS. The enhanced ability to derive the cells implicated in the disease will undoubtedly accelerate research for MS and many other diseases,” said Susan L. Solomon, NYSCF Chief Executive Officer.
Take me to the complete story . . .
The Latest on: Cell replacement therapy
via Google News
The Latest on: Cell replacement therapy
- Women’s Health Initiative to continueon February 24, 2021 at 5:37 pm
Nearly 30 years after it was launched, the Women’s Health Initiative is still going strong and will continue to run for several more years, thanks to a new grant from the NIH.
- FDA Places Clinical Hold on Sickle Cell Gene Therapyon February 24, 2021 at 3:32 pm
The retooled lentivirus used in the SCD trials, LentiGlobin, delivers a beta globin gene with one amino acid replacement to hematopoietic stem cells outside the patient's body. The modified cells are ...
- A new combination therapy for treating rare, fatal Sanfilippo syndrome in childrenon February 24, 2021 at 3:27 pm
A study aiming to develop a new therapeutic technique could bring a revolution in our approach to treating rare, fatal Sanfilippo syndrome, a disorder that affects children as young as 2 years old and ...
- A combination therapy for treating severe neurological childhood disorderson February 24, 2021 at 1:20 pm
A study aiming to develop a new therapeutic technique could bring a revolution in our approach to treating rare, fatal Sanfilippo syndrome, a disorder that affects children as young as 2 years old and ...
- Testosterone Replacement Therapy Market Latest Research On Industry Growth, Trends, Top Players, & Key Regions By 2027on February 23, 2021 at 10:10 pm
Global Testosterone Replacement Therapy Market is expected to exceed more than US$ 1.0 billion by 2024 at CAGR of 4% in ...
- UMass Medical School joins JDRF Center of Excellence in New England to advance type 1 diabetes researchon February 23, 2021 at 7:01 am
Five UMass Medical School scientists from the UMass Diabetes Center of Excellence are part of the JDRF Center of Excellence in New England that launched Feb. 23. The goal of the cross-institutional ...
- Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) Receives $4.50 Average Price Target from Analystson February 21, 2021 at 4:00 pm
Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) has been given a consensus recommendation of “Buy” by the six brokerages that are currently covering the stock, MarketBeat reports. One equities ...
- Bile duct organoids could be used as cell therapy for regenerative medicineon February 19, 2021 at 4:50 am
For the first time, scientists have grown bile duct organoids that could repair damaged ducts and livers as a new cell therapy.
- Lab-grown 'mini-bile ducts' used to repair human livers in regenerative medicine firston February 18, 2021 at 11:05 am
Scientists have used a technique to grow bile duct organoids—often referred to as 'mini-organs' - in the lab and shown that these can be used to repair damaged human livers. This is the first time ...
- T-Cell Therapy Market Overview with Detailed Analysis, Competitive landscape, Forecast to 2027on February 15, 2021 at 11:46 am
DBMR has added a new report titled T-Cell Therapy Market with analysis provides the insights which bring marketplace clearly into the focus and thus help organizations make better decisions. The data ...
via Bing News
